OneTwenty
OneTwenty is an early-stage health tech start-up that develops multiple machine learning based solutions for people with diabetes as well as medtech companies for sensor optimization, biomarker prediction, glucoregulatory models, and iAGC. The company solutions demonstrates unprecedented precision in blood glucose prediction 120 minutes in advance. OneTwenty revolutionizes the life of people with Type 1 diabetes.
OneTwenty
OneTwenty is an early-stage health tech start-up that develops multiple machine learning based solutions for people with diabetes as well as medtech companies for sensor optimization, biomarker prediction, glucoregulatory models, and iAGC. The company solutions demonstrates unprecedented precision in blood glucose prediction 120 minutes in advance. OneTwenty revolutionizes the life of people with Type 1 diabetes.
TL;DR
Headquarters: Zürich, Switzerland
Core product: bioX® — ML platform for glucose prediction, sensor optimization, and automated insulin delivery
Stage / funding signal: Closed first financing Jan 2024 led by DvH Ventures
Employees (approx.): 5
Company Overview
Problem Domain
Diabetes management and medtech sensor/insulin-delivery optimization
Founded
2022
Industry
Health technology / MedTech
Funding Track Record
Reported as the company's first financing; round amount not disclosed in provided evidence.
Investor Signal
“Dieter von Holtzbrinck Ventures led first financing in Jan 2024; other named investors reported in coverage include Tiny Supercomputer Investment Company and Tim Juergens.”